Theranexus Stock (ALTHX.PA): Analysis & Outlook

Theranexus is an innovative biopharmaceutical company specializing in the treatment of neurological diseases. Theranexus stock (ALTHX.PA) is a high-potential play that has been attracting growing interest from investors. In this article, we take a close look at everything worth knowing about Theranexus stock — from recent Theranexus news to its clinical trials — to determine whether it is a good idea to invest.

Live Stock Price ()

Right now, you can buy stock at per share. Since the start of the trading day, the share price has moved by %.

At the opening bell, stock traded at . During the session, the share price climbed to a high of and slipped to a low of , and the day’s closing price currently stands at .

Should You Buy Theranexus Stock? Key Figures

Over the past 52 weeks, stock — the ALTHX.PA share price — climbed to a high of , while the lowest point reached over the same 52 weeks was .

Over the last 5 trading sessions, here is how the price of () has moved:

Should You Buy Stock?

At the moment, stock trades at and pays a dividend of per share. The dividend yield on stock works out at % per year if you buy shares at the current price.

Also consider choosing a broker with the advantage of a full-service offer for buying stocks from all over the world. It will make it easier to diversify your portfolio later on.

Analyst Consensus and Price Targets for Stock

Stock Dividend

The Shareholders of

Here are the current shareholders of :

• DNCA Finance SA – 2.537%
• ACA Asset Management Company & Associés SASU – 0.2734%
• NOVACAP Asset Management SA – 0.1719%

Competitors of

While direct competitors vary depending on specialization and geographic reach, here are a few companies that could be considered potential competitors of :

1. Biogen: Biogen is a global biopharmaceutical company focused on neuroscience, with treatments developed for multiple sclerosis, Parkinson’s disease and Alzheimer’s disease, among others. (Buy Biogen stock)
2. Eisai Co., Ltd.: Eisai is a Japanese pharmaceutical company that develops drugs for a wide range of neurological disorders, including Alzheimer’s disease, Parkinson’s disease and epilepsy.
3. Acorda Therapeutics: Acorda Therapeutics is a biopharmaceutical company focused on developing drugs for neurological disorders such as multiple sclerosis and Parkinson’s disease.
4. Teva Pharmaceutical Industries Ltd.: Teva is one of the largest generic drug manufacturers in the world, but it also develops medicines for neurological disorders, including migraine and multiple sclerosis. (Buy Teva Pharmaceutical stock)
5. Axovant Gene Therapies: Axovant is a biotechnology company focused on gene therapies for neurological diseases, including Parkinson’s disease and rare disorders.
6. Vertex Pharmaceuticals: Vertex focuses primarily on developing drugs for rare genetic diseases, but its treatments may also have implications in the field of neurological disorders. (Buy Vertex Pharmaceuticals stock)

These companies, among others, represent part of the competition Theranexus could face in developing and commercializing its treatments for neurological disorders. Research efforts, clinical progress, intellectual property and commercial strategy are all factors that shape the competition between these companies.

Customers of

Theranexus is a biopharmaceutical company focused on researching and developing innovative treatments for neurological disorders. As such, its main customers would be the following players in the medical and pharmaceutical ecosystem:

• Patients: Patients with neurological disorders could be the end users of the treatments developed by Theranexus. These treatments aim to improve quality of life and relieve the symptoms of conditions such as Alzheimer’s disease, Parkinson’s disease and sleep disorders.
• Healthcare professionals: Physicians, neurologists, pharmacists and other healthcare professionals play a key role in prescribing and using the treatments developed by Theranexus. The company could partner with healthcare professionals to promote its products and ensure they are used correctly.
• Medical institutions: Hospitals, clinics and other medical institutions could become Theranexus customers, whether to source treatments or to take part in clinical trials.
• Partner pharmaceutical companies: Theranexus could collaborate with other pharmaceutical companies to develop, produce and commercialize its products. Such partnerships may involve licensing, co-development or commercialization agreements.
• Investors: Investors — venture capital funds, private equity firms and individual shareholders — finance Theranexus’s development and can benefit from the company’s potential long-term growth.

These examples are not exhaustive, and the list of customers of may vary depending on its commercial strategy and growth initiatives.

Why Invest in Stock

Is Theranexus a good investment? Investing in Theranexus stock may offer several potential advantages for investors interested in the biopharmaceutical sector and in the development of innovative treatments for neurological disorders. Here are a few reasons why some investors might consider buying Theranexus stock:

• Market growth potential: Neurological disorders represent a fast-expanding area of medicine, driven by the rising prevalence of these conditions and growing demand for effective treatments.
• Promising pipeline: the Theranexus pipeline includes several promising drug candidates targeting a range of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease and sleep disorders. Positive readouts from the Theranexus clinical trials could lift the value of the stock.
• Strategic collaborations: Theranexus can enter into partnerships with other pharmaceutical or biotechnology companies, which can provide additional resources for product development and broaden its access to global markets.
• Technological innovation: The company could develop innovative therapeutic approaches based on cutting-edge technologies, such as network neurobiology, which could offer significant competitive advantages over existing treatments.
• Financial performance: If Theranexus achieves its clinical development goals, obtains regulatory approvals and successfully brings its products to market, the result could be revenue and profit growth — a driver of the share price.

Investing in a specific stock such as requires thorough research and a clear understanding of the risks and opportunities associated with this particular company.

You can invest in Theranexus stock on the Euronext Growth Paris market (Euronext stock exchange). Like most French biotech stocks, it can also be held in a PEA — France’s tax-advantaged share savings plan — since the company is incorporated in France.

This article is for educational purposes only and does not constitute investment advice. The investments discussed carry a risk of capital loss.